AbbVie's Post-Humira Triumph: Skyrizi and Rinvoq Drive Sector-Leading Growth

Related Articles

Is the Mining Sector Still a Golden Opportunity Post-Earnings

6 months ago

Goldman Sachs' Q1 Triumph: A Beacon of IB Strength Amidst Banking Sector Caution

2 months ago

AbbVie and Genmab's Epcoritamab: Why the Lymphoma Breakthrough is Still Undervalued

3 months ago

Reddit's Dip: A Buying Opportunity as AI Licensing and Ads Drive Growth

2 months ago

Category

You may also like

Stock News•3 weeks ago

AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next

AbbVie's immunology franchise is being driven by Skyrizi and Rinvoq, with new indications, acquisitions, and partnerships building the next wave of growth.

ABBV

Share

Stock News•4 weeks ago

AbbVie: Shares Defy Sell-Side Downgrades, And That's Bullish (Technical Analysis)

AbbVie shares held gains despite sell-side downgrades, supported by Q2 beats from Skyrizi and Rinvoq. The $11B Apogee acquisition adds pipeline depth with modest near-term EPS dilution, and technicals...

ABBV

Share

Stock News•2 months ago

AbbVie Inc. (ABBV) Q2 2026 Earnings Call Transcript

AbbVie reported Q2 2026 earnings, with results reflecting continued performance amid key product dynamics. Management discussed growth drivers and challenges, providing updated guidance for the remain...

ABBV

Share